التداخل بين أسيتازولاميد وفينترمين وتوبيرامات

Avoid use of phentermine and topiramate extended-release capsules with other carbonic anhydrase inhibitors.

If concomitant use of phentermine and topiramate extended-release capsules with another carbonic anhydrase inhibitor is unavoidable, the patient should be monitored for the appearance or worsening of metabolic acidosis.

Concomitant use of phentermine and topiramate extended-release capsules and a carbonic anhydrase inhibitor may increase the severity of metabolic acidosis and may also increase the risk of kidney stone formation [see Warnings and Precautions (5.10) ] .

In addition, when phentermine and topiramate extended-release capsules are used in conjunction with nonpotassium sparing diuretics this may further potentiate potassium-wasting.

…phentermine and topiramate extended-release capsules dosage reduction or discontinuation if cognitive dysfunction persists [see Warnings and Precautions (5.5) ] Non-Potassium Sparing Diuretics Clinical Impact Concurrent use of phentermine and topiramate extended-release capsules with non-potassium sparing diuretics may potentiate the potassium-wasting action of…

By decreasing the gastrointestinal absorption of primidone, acetazolamide may decrease serum concentrations of primidone and its metabolites, with a consequent possible decrease in anticonvulsant effect.

Acetazolamide decreases urinary excretion of amphetamine and may enhance the magnitude and duration of their effect.